

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waiver under 18 U.S.C. §208(b)(3)

John T. Farrar, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: July 24, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 021,801, proposed trade name Orplatna (satraplatin capsules), originally developed by Johnson Matthey Pharmaceuticals, a subsidiary of Johnson Matthey PLC, with licensing rights to Spectrum Pharmaceuticals. Spectrum Pharmaceuticals licensed the global rights to GPC Biotech AG, proposed indication for the treatment of patients with androgen independent (hormone refractory) prostate cancer (HRPC) that has failed prior chemotherapy, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Advisory Board	Competitor	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

_____/S/
Signature of SGE

June 8, 2007
Date